Top

Published in:

01-08-2017 | IM - REVIEW

Vasculitis for the internist: focus on ANCA-associated vasculitis

Authors: Benjamin Chaigne, Loïc Guillevin

Published in: Internal and Emergency Medicine | Issue 5/2017

Abstract

Vasculitides comprise several diseases affecting vessels of different sizes, mainly arteries, but also capillaries and veins. Antineutrophil cytoplasm antibody-associated vasculitides (AAVs) belong to the systemic necrotizing small-vessel vasculitis group that comprises granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. Internists often see AAV patients, and although their outcomes are usually good, the disease can be responsible for morbidity and mortality. Herein, after reviewing the literature, we concentrate on selected aspects important for the internist, including classification, diagnostic dilemmas, treatment novelties, and follow-up.

Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606. doi:10.1007/s10157-013-0869-6 CrossRefPubMedPubMedCentral

Fraison J-B, Sève P, Dauphin C et al (2016) Kawasaki disease in adults: observations in France and literature review. Autoimmun Rev 15:242–249. doi:10.1016/j.autrev.2015.11.010 CrossRefPubMed

Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33:S-77–83PubMedPubMedCentral

Audemard-Verger A, Pillebout E, Guillevin L et al (2015) IgA vasculitis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev 14:579–585. doi:10.1016/j.autrev.2015.02.003 CrossRefPubMed

Jachiet M, Flageul B, Deroux A et al (2014) The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of 57 patients. Arthritis Rheumatol (Hoboken, NJ). doi:10.1002/art.38956

Quartuccio L, Isola M, Corazza L et al (2014) Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 53:2209–2213. doi:10.1093/rheumatology/keu271 CrossRef

Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281. doi:10.1002/art.37721 CrossRefPubMed

Chaigne B, Guillevin L (2016) Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides. Clin Exp Rheumatol 34:S121–S128PubMed

Kussmaul A, Maier R (1866) Uber eine bisher nicht beschriebene eigenthumliche arterienerkran-kung (periarteritis nodosa), die mit morbus brightii und rapid fortschreitender allgemeiner muskellahmung einhergeht. Dtsch Arch Klin Med 1:484–518

10.

Wohlwill F (1923) Über die nur mikroskopisch erkennbare Form der Periarteritis nodosa. Virchows Arch Pathol Anat Physiol 246:36CrossRef

11.

Wegener F (1987) On generalised septic vessel diseases. By Friedrich Wegener, 1937 (translation). Thorax 42:918–919CrossRefPubMedPubMedCentral

12.

Hunder GG, Arend WP, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065–1067CrossRefPubMed

13.

Fries JF, Hunder GG, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33:1135–1136CrossRefPubMed

14.

Chaigne B, Terrier B, Thieblemont N et al (2016) Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis. Autoimmun Rev 15:139–145. doi:10.1016/j.autrev.2015.10.006 CrossRefPubMed

15.

Sinico RA, Di Toma L, Maggiore U et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52:2926–2935. doi:10.1002/art.21250 CrossRefPubMed

16.

Lyons PA, Rayner TF, Trivedi S et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214–223. doi:10.1056/NEJMoa1108735 CrossRefPubMedPubMedCentral

17.

Damoiseaux J, Csernok E, Rasmussen N et al (2016) Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. doi:10.1136/annrheumdis-2016-209507 PubMed

18.

Csernok E, Moosig F (2014) Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 10:494–501. doi:10.1038/nrrheum.2014.78 CrossRefPubMed

19.

Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594. doi:10.1136/annrheumdis-2016-209133 CrossRefPubMed

20.

Aasarød K, Bostad L, Hammerstrøm J et al (2001) Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 16:953–960CrossRefPubMed

21.

Devaney KO, Travis WD, Hoffman G et al (1990) Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14:555–564CrossRefPubMed

22.

Schnabel A, Holl-Ulrich K, Dalhoff K et al (1997) Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J 10:2738–2743CrossRefPubMed

23.

Travis WD, Hoffman GS, Leavitt RY et al (1991) Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15:315–333CrossRefPubMed

24.

Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628–1636. doi:10.1681/ASN.2010050477 CrossRefPubMed

25.

Berden AE, Jones RB, Erasmus DD et al (2012) Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23:313–321. doi:10.1681/ASN.2011040330 CrossRefPubMed

26.

Hauer HA, Bajema IM, Hagen EC et al (2002) Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transpl 17:587–596CrossRef

27.

Hruskova Z, Honsova E, Berden AE et al (2014) Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrol Dial Transpl 29:1728–1732. doi:10.1093/ndt/gfu042 CrossRef

28.

Visconti L, Cernaro V, Ricciardi CA et al (2016) Renal biopsy: still a landmark for the nephrologist. World J Nephrol 5:321–327. doi:10.5527/wjn.v5.i4.321 CrossRefPubMedPubMedCentral

29.

Rasmussen N, Jayne D, Abramowicz D et al (1995) European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 101(Suppl 1):29–34

30.

Hellmich B, Flossmann O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617. doi:10.1136/ard.2006.062711 CrossRefPubMed

31.

Rosenbaum JT, Choi D, Wilson DJ et al (2015) Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling. Exp Mol Pathol 99:271–278. doi:10.1016/j.yexmp.2015.07.002 CrossRefPubMedPubMedCentral

32.

Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551. doi:10.1056/NEJMra1104650 CrossRefPubMed

33.

Della-Torre E, Lanzillotta M, Campochiaro C et al (2016) Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: a case report and review of the literature. Medicine (Baltimore) 95:e4633. doi:10.1097/MD.0000000000004633 CrossRef

34.

Rachapalli SM, Kiely PDW (2008) Cocaine-induced midline destructive lesions mimicking ENT-limited Wegener’s granulomatosis. Scand J Rheumatol 37:477–480. doi:10.1080/03009740802192043 CrossRefPubMed

35.

Borner U, Landis BN, Banz Y et al (2012) Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy 26:475–480. doi:10.2500/ajra.2012.26.3825 CrossRefPubMed

36.

Holle JU, Gross WL, Holl-Ulrich K et al (2010) Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 69:1934–1939. doi:10.1136/ard.2010.130203 CrossRefPubMed

37.

De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469. doi:10.1002/art.21142 CrossRefPubMed

38.

Thickett DR, Richter AG, Nathani N et al (2006) Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Rheumatology (Oxford) 45:261–268. doi:10.1093/rheumatology/kei217 CrossRef

39.

Callister MEJ, Baldwin DR, Akram AR et al (2015) British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 70(Suppl 2):ii1–ii54. doi:10.1136/thoraxjnl-2015-207168 CrossRefPubMed

40.

Harper L (2013) L42. Morbidity in patients with ANCA-associated vasculitis. Presse Med 42:612–616. doi:10.1016/j.lpm.2013.01.040 CrossRefPubMed

41.

Shang W, Ning Y, Xu X et al (2015) Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. doi:10.1371/journal.pone.0126016

42.

Jones RB, Tervaert JWC, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220. doi:10.1056/NEJMoa0909169 CrossRefPubMed

43.

Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232. doi:10.1056/NEJMoa0909905 CrossRefPubMedPubMedCentral

44.

Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780. doi:10.1056/NEJMoa1404231 CrossRefPubMed

45.

Jones RB (2014) Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Nephron Clin Pract 128:243–249. doi:10.1159/000368580 CrossRefPubMed

46.

Alberici F, Smith RM, Jones RB et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153–1160. doi:10.1093/rheumatology/keu452 CrossRef

47.

Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327–333. doi:10.1136/ard.2011.153601 CrossRefPubMed

48.

Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417–427. doi:10.1056/NEJMoa1213277 CrossRefPubMed

49.

Puéchal X, Pagnoux C, Perrodeau É et al (2016) Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol (Hoboken, NJ) 68:690–701. doi:10.1002/art.39450 CrossRef

50.

Miloslavsky EM, Specks U, Merkel PA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol (Hoboken, NJ) 67:1629–1636. doi:10.1002/art.39104 CrossRef

51.

Jones RB, Furuta S, Tervaert JWC et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74:1178–1182. doi:10.1136/annrheumdis-2014-206404 CrossRefPubMed

52.

Walsh M, Faurschou M, Berden A et al (2014) Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 9:1571–1576. doi:10.2215/CJN.00100114 CrossRefPubMedPubMedCentral

53.

Turnbull J, Harper L (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 23:391–401. doi:10.1016/j.berh.2009.04.002 CrossRefPubMed

54.

Conway R, Low C, Coughlan RJ et al (2015) Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 45:156–162. doi:10.1016/j.semarthrit.2015.05.003 CrossRefPubMed

55.

Siramolpiwat S, Sakonlaya D (2017) Clinical and histologic features of Azathioprine-induced hepatotoxicity. Scand J Gastroenterol. doi:10.1080/00365521.2017.1311936 PubMed

56.

Roberts DM, Jones RB, Smith RM et al (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60–65. doi:10.1016/j.jaut.2014.11.009 CrossRefPubMed

57.

Mélet J, Mulleman D, Goupille P et al (2013) Rituximab-induced T-cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. doi:10.1002/art.38107 PubMed

58.

Martin-Garrido I, Carmona EM, Specks U, Limper AH (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest 144:258–265. doi:10.1378/chest.12-0477 CrossRefPubMed

59.

Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548. doi:10.1002/art.33361 CrossRefPubMed

60.

Slot MC, Tervaert JWC, Boomsma MM, Stegeman CA (2004) Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 51:269–273. doi:10.1002/art.20234 CrossRefPubMed

61.

Thai L-H, Charles P, Resche-Rigon M et al (2014) Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 13:313–318. doi:10.1016/j.autrev.2013.11.003 CrossRefPubMed

62.

Shi Y-Y, Li Z-Y, Zhao M-H, Chen M (2015) The CD4 lymphocyte count is a better predictor of overall infection than the total lymphocyte count in ANCA-associated vasculitis under a corticosteroid and cyclophosphamide regimen: a retrospective cohort. Medicine (Baltimore) 94:e843. doi:10.1097/MD.0000000000000843 CrossRef

63.

Goupil R, Brachemi S, Nadeau-Fredette A-C et al (2013) Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 8:416–423. doi:10.2215/CJN.07300712 CrossRefPubMed

64.

Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20. doi:10.1056/NEJM199607043350103 CrossRefPubMed

65.

Zycinska K, Wardyn KA, Zielonka TM et al (2009) Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res 14(Suppl 4):265–267CrossRefPubMedPubMedCentral

66.

Guillevin L, Guittard T, Bletry O et al (1987) Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 165:165–172CrossRefPubMed

67.

Konishi M, Koarada S, Yamaguchi K et al (2011) Case of microscopic polyangiitis and giant cell arteritis after influenza vaccination. Nihon Rinsho Meneki Gakkai Kaishi 34:154–161CrossRefPubMed

68.

Stassen PM, Sanders J-SF, Kallenberg CGM, Stegeman CA (2008) Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transpl 23:654–658. doi:10.1093/ndt/gfm640 CrossRef

69.

Duggal T, Segal P, Shah M et al (2013) Antineutrophil cytoplasmic antibody vasculitis associated with influenza vaccination. Am J Nephrol 38:174–178. doi:10.1159/000354084 CrossRefPubMed

70.

Holvast A, Stegeman CA, Benne CA et al (2009) Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 68:873–878. doi:10.1136/ard.2008.092924 CrossRefPubMed

71.

Holvast A, de Haan A, van Assen S et al (2010) Cell-mediated immune responses to influenza vaccination in Wegener’s granulomatosis. Ann Rheum Dis 69:924–927. doi:10.1136/ard.2009.112813 CrossRefPubMed

72.

Groh M, Puéchal X, Terrier B et al (2016) VAC-04—Echec de la vaccination antipneumococcique en phase d’attaque du traitement des vascularites à ANCA: l’étude pneumovas pilote 1. Med Mal Infect 46:111. doi:10.1016/S0399-077X(16)30530-3 CrossRef

73.

Sangle SR, Vounotrypidis P, Briley A et al (2015) Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. Rheumatology (Oxford) 54:1582–1586. doi:10.1093/rheumatology/kev018 CrossRef

74.

Huong DL, Amoura Z, Duhaut P et al (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571–2576PubMed

75.

Grygiel-Górniak B, Puszczewicz M (2015) Granulomatosis with polyangiitis in pregnancy—clinical implications and treatment possibilities. Eur Rev Med Pharmacol Sci 19:2331–2335PubMed

76.

Pagnoux C, Le Guern V, Goffinet F et al (2011) Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. Rheumatology (Oxford) 50:953–961. doi:10.1093/rheumatology/keq421 CrossRef

77.

Guillevin L, Pagnoux C, Seror R et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19–27. doi:10.1097/MD.0b013e318205a4c6 CrossRef

78.

Bourgarit A, Le Toumelin P, Pagnoux C et al (2005) Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84:323–330CrossRef

79.

Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol (Hoboken, NJ) 67:1117–1127. doi:10.1002/art.39011 CrossRef

Title: Vasculitis for the internist: focus on ANCA-associated vasculitis
Authors: Benjamin Chaigne
Loïc Guillevin
Publication date: 01-08-2017
Publisher: Springer International Publishing
Published in: Internal and Emergency Medicine / Issue 5/2017
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-017-1683-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

The diagnosis of neglected tropical diseases (NTDs) in Italy: comment

An Italian version of the Ottawa Crisis Resource Management Global Rating Scale: a reliable and valid tool for assessment of simulation performance

New diagnosis of von Hippel–Lindau on CT

Is it reasonable to use a lower DOAC dose in some patients with VTE? NO

Characteristics of patients with an unplanned admission to an acute palliative care unit

The diagnosis of neglected tropical diseases (NTDs) in Italy: reply

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage